ICU Medical (NASDAQ:ICUI) Insider Sells $401,220.00 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) insider Ben Sousa sold 2,250 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total transaction of $401,220.00. Following the completion of the transaction, the insider directly owned 3,076 shares in the company, valued at $548,512.32. This trade represents a 42.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $182.98 on Friday. ICU Medical, Inc. has a 12 month low of $112.50 and a 12 month high of $192.85. The firm has a market capitalization of $4.57 billion, a P/E ratio of 155.07, a P/E/G ratio of 2.56 and a beta of 0.74. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The company’s fifty day moving average price is $156.56 and its 200 day moving average price is $141.96.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.46. The company had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. ICU Medical’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, sell-side analysts predict that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ICUI shares. KeyCorp raised their price target on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 21st. BTIG Research boosted their price objective on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Needham & Company LLC increased their price objective on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday, August 7th. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Piper Sandler lifted their target price on shares of ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $192.80.

Hedge Funds Weigh In On ICU Medical

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of ICU Medical in the second quarter valued at about $550,250,000. Jupiter Topco LLC acquired a new position in ICU Medical during the second quarter worth about $407,786,000. Millennium Management LLC increased its holdings in ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after buying an additional 690,694 shares in the last quarter. Norges Bank purchased a new position in ICU Medical in the fourth quarter valued at about $58,083,000. Finally, Reinhart Partners LLC. acquired a new stake in shares of ICU Medical during the 2nd quarter valued at approximately $46,148,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.